{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:51:38Z","timestamp":1786981898158,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00992-4","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T05:02:30Z","timestamp":1693026150000},"page":"685-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma"],"prefix":"10.1007","volume":"18","author":[{"given":"Lan-Hsi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory K.","family":"Mavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna R.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3824-3417","authenticated-orcid":false,"given":"Andrew K. L.","family":"Goey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"3","key":"992_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","volume":"26","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Phelan JD, Wilson WH. Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Cancer J. 2020;26(3):195\u2013205.","journal-title":"Cancer J"},{"key":"992_CR2","doi-asserted-by":"crossref","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040\u20135.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498\u2013505.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"992_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - B-Cell Lymphomas, Version 2.2023. 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 1 May 2023."},{"issue":"27","key":"992_CR5","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"25","key":"992_CR6","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1182\/blood-2009-12-259754","volume":"116","author":"SH Olejniczak","year":"2010","unstructured":"Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, Riaz W, Mavis C, et al. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus-sensitive B-NHL cells. Blood. 2010;116(25):5605\u201314.","journal-title":"Blood"},{"issue":"5","key":"992_CR7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","volume":"14","author":"SH Olejniczak","year":"2008","unstructured":"Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008;14(5):1550\u201360.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"992_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(4):667\u201375.","journal-title":"J Clin Oncol"},{"issue":"18 Pt 1","key":"992_CR9","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","volume":"13","author":"RC Kane","year":"2007","unstructured":"Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18 Pt 1):5291\u20134.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"992_CR10","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1200\/JCO.2005.05.014","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O\u2019Connor OA. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin Oncol. 2005;23(26):6429\u201336.","journal-title":"J Clin Oncol"},{"issue":"13","key":"992_CR11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"992_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood-2005-09-3731","volume":"107","author":"A Younes","year":"2006","unstructured":"Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006;107(4):1731\u20132.","journal-title":"Blood"},{"issue":"24","key":"992_CR13","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069\u201376.","journal-title":"Blood"},{"issue":"25","key":"992_CR14","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389\u201395.","journal-title":"J Clin Oncol"},{"issue":"10","key":"992_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944\u201353.","journal-title":"N Engl J Med"},{"issue":"5","key":"992_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/bjh.12452","volume":"162","author":"JJ Gu","year":"2013","unstructured":"Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013;162(5):657\u201369.","journal-title":"Br J Haematol"},{"issue":"7","key":"992_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/bloodadvances.2022008543","volume":"7","author":"P Torka","year":"2023","unstructured":"Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, et al. Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. Blood Adv. 2023;7(7):1146\u201355.","journal-title":"Blood Adv"},{"issue":"5","key":"992_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jcph.850","volume":"57","author":"Y Ou","year":"2017","unstructured":"Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, et al. Population pharmacokinetics and exposure-response relationship of carfilzomib in patients with multiple myeloma. J Clin Pharmacol. 2017;57(5):663\u201377.","journal-title":"J Clin Pharmacol"},{"key":"992_CR19","unstructured":"European Medicines Agency-Committee for Medicinal Products for Human Use. Group of Variations Including an Extension of Indication Assessment Report: Carfilzomib. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kyprolis-h-c-3790-ii-0001-g-epar-assessment-report-variation_en.pdf. Accessed 24 May 2022."},{"key":"992_CR20","unstructured":"US Food and Drug Administration-Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s): Carfilzomib. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202714Orig1s000ClinPharmR.pdf. Accessed 24 May 2022."},{"issue":"5","key":"992_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40262-023-01242-6","volume":"62","author":"MR Yago","year":"2023","unstructured":"Yago MR, Mehta K, Bose M, Bhagwat S, Chopra VS, Dutta S, et al. Mechanistic pharmacokinetic\/pharmacodynamic modeling in support of a patient-convenient, longer dosing interval for carfilzomib, a covalent inhibitor of the proteasome. Clin Pharmacokinet. 2023;62(5):779\u201388.","journal-title":"Clin Pharmacokinet"},{"key":"992_CR22","unstructured":"US Food and Drug Administration. Bioanalytical Method Validation: Guidance for Industry. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 17 May 2022."},{"issue":"5","key":"992_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"992_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.71","volume":"3","author":"RN Upton","year":"2014","unstructured":"Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2014;3(1): e88.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"992_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40262-019-00803-y","volume":"59","author":"JM Janssen","year":"2020","unstructured":"Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, et al. A semi-mechanistic population pharmacokinetic\/pharmacodynamic model of bortezomib in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Pharmacokinet. 2020;59(2):207\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"992_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2(4): e38.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"992_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/psp4.12015","volume":"4","author":"RV Overgaard","year":"2015","unstructured":"Overgaard RV, Ingwersen SH, Tornoe CW. Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):565\u201375.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"992_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10928-015-9445-x","volume":"42","author":"L Zhang","year":"2015","unstructured":"Zhang L, Mager DE. Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. J Pharmacokinet Pharmacodyn. 2015;42(5):541\u201352.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00992-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T05:17:58Z","timestamp":1695446278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00992-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00992-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]},"assertion":[{"value":"12 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Amgen and the National Cancer Institute (NCI) grant P30CA016056 involving the use of Roswell Park Comprehensive Cancer Center\u2019s BMPK Shared Resource.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.T. received consulting fees from ADC therapeutics, TG therapeutics, Genmab, Genentech, Lilly USA, and Seagen. F.J.H.I. is an advisory Board Member for Amgen, Karyopharm Therapeutics, Celgene Corporation, Kura Oncology, AbbVie Inc., Seattle Genetics Inc., Epizyme, Pharmacyclics, Gilead, Kite Pharma, Novartis, and MorphoSys. F.J.H.I. also is a member of the Speaker Bureau of MorphoSys. Lan-Hsi Lin, Mohammad Ghasemi, Sarah M. Burke, Cory K. Mavis, Jenna R. Nichols, Donald E. Mager, and Andrew K.L. Goey declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The clinical study was performed per the International Council for Harmonization Good Clinical Practice Guideline and the ethical principles of the Declaration of Helsinki and was approved by the institutional review board of Roswell Park Comprehensive Cancer Center (protocol no. I-240813).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent prior to enrollment in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The NONMEM control stream for nonlinear-mixed effect PK\/PD modeling has been made available in Supplementary File S6.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"DEM, FJHI, and AKLG designed the project and provided supervision; LL and MG developed the PK\/PD model and performed the data analysis; SMB performed the LC\u2013MS\/MS analysis; CKM performed the proteasome activity analysis; JRN, PT, and FJHI collected clinical data; FJHI acquired funding; DEM, FJHI, and AKLG supported interpretation of the results; LL and A.K.L.G. wrote the original draft; and all authors critically read, revised, and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}